Information Provided By: 
Fly News Breaks for September 18, 2017
TEVA
Sep 18, 2017 | 07:31 EDT
RBC Capital analyst Randall Stanicky cut his price target on Teva as he believes that the new CEO will need time "to come up to speed," and the analyst is unsure what strategic options the new CEO can take that the board has not already considered. Stanicky says that the company's debt load "looks severe," while it faces multiple additional headwinds, including generic Copaxone and headwinds to its own generic business. He cut his price target on the shares to $15 from $21 and keeps an Underperform rating on the name.
News For TEVA From the Last 2 Days
There are no results for your query TEVA
